Cadrenal Therapeutics Inc. (NASDAQ: CVKD) Featured in Coverage of NobleCon19
Cadrenal Therapeutics (NASDAQ: CVKD) is developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner), to prevent heart attacks, strokes, and deaths due to blood clots in patients with certain rare medical conditions who require chronic anticoagulation. Tecarfarin has orphan drug and Fast Track designations for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage kidney disease (“ESKD”) with…